Sino Biopharmaceutical
Sino Biopharmaceutical
Sino Biopharmaceutical is a leading Chinese innovative research and R&D-driven pharmaceutical group
Sino Biopharmaceutical, founded in 2020 and headquartered in Hong Kong, is the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the entire industry chain of pharmaceutical R&D platforms, intelligent production, and strong sales systems. Established by Xie Qirun, it was listed on the Hong Kong Stock Exchange In September of the same year as the foundation. The company's major shareholders are Thousand Eagles Limited, FRANCE INVESTMENT (CHINA 1) GROUP LIMITED, Remarkable Industries Limited, and Validated Profits Limited. Rivals with the direct and indirect competition with Sino Biopharmaceutical include Lansen Pharmaceutical, Chia Tai Enterprises, Hansoh Pharma.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Research
Real Estate, Consumer Discretionary, IndustrialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
May 28, 2020 12:40 PM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Healthcare
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Healthcare
CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM
There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?
Apr 27, 2022 09:45 PM
Briefing Apr 19, 2022 07:44 AM
· Healthcare
China biopharmaceutical: the fifth indication of anti-tumor drug "arotinib hydrochloride capsule" has been approved
Briefing Aug 18, 2021 07:54 PM
Jin Litai: the prices of various types of cathodic electrophoretic paint products rise by 10% - 20%
See more
Related Companies
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.